Display options
Cite
Ibrahim MA, El-Badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J. 2013;22(2):149-56doi: 10.1016/j.jsps.2013.01.011.
Ibrahim, M. A., & El-Badry, M. (2014). Formulation of immediate release pellets containing famotidine solid dispersions. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 22(2), 149-56. https://doi.org/10.1016/j.jsps.2013.01.011
Ibrahim, Mohamed Abbas, and El-Badry, Mahmoud. "Formulation of immediate release pellets containing famotidine solid dispersions." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 22,2 (2014): 149-56. doi: https://doi.org/10.1016/j.jsps.2013.01.011
Ibrahim MA, El-Badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J. 2014 Apr;22(2):149-56. doi: 10.1016/j.jsps.2013.01.011. Epub 2013 Feb 16. PMID: 24648827; PMCID: PMC3950527.
Copy Download .nbib Format: NLM
Share it on

Saudi Pharm J. 2014 Apr;22(2):149-56. doi: 10.1016/j.jsps.2013.01.011. Epub 2013 Feb 16.

Formulation of immediate release pellets containing famotidine solid dispersions.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Mohamed Abbas Ibrahim, Mahmoud El-Badry

Affiliations

  1. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
  2. Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

PMID: 24648827 PMCID: PMC3950527 DOI: 10.1016/j.jsps.2013.01.011

Abstract

Famotidine (FM) is a potent H2-receptor antagonist used for the treatment of peptic ulcer. It has a low and variable bioavailability which is attributed to its low water solubility. In this study, the dissolution of the drug was enhanced by a preparation of solid dispersion using two hydrophilic carriers, namely Gelucire 50/13 and Pluronic F-127. The prepared solid dispersions were characterized by differential scanning calorimetry (DSC), which indicated that there were no signs of interaction of the drug with the carriers used in the case of solid dispersions containing higher polymeric contents (1:3 and 1:5). FM solid dispersions in the matrices of Gelucire 50/13 and Pluronic F-127 (1:3) were used to prepare pellets. The scanning electron microscope (SEM) images of pellets showed that the pellets have spherical shape and their size depends on the carrier used. The dissolution of the drug from either solid dispersion or pellets was performed. The dissolution study depicted that, the presence of the drug in solid dispersion enhanced its dissolution in comparison with the drug itself. Also, the drug release from the manufactured pellets was found to be improved in the case of solid dispersions (drug:carrier 1:3). A complete drug release occurred after 30 min from pellets containing solid dispersions, while only about 30% of the loaded FM was released from pellets containing untreated drug after 2 h.

Keywords: Dissolution; Famotidine; Pellets; Solid dispersion

References

  1. J Pharm Sci. 1971 Sep;60(9):1281-302 - PubMed
  2. Eur J Clin Pharmacol. 1988;33 Suppl:S3-7 - PubMed
  3. Drug Dev Ind Pharm. 2006 Feb;32(2):141-50 - PubMed
  4. Drug Dev Ind Pharm. 2009 Mar;35(3):297-304 - PubMed
  5. Pharm Dev Technol. 2007;12(1):43-53 - PubMed
  6. Arch Pharm Res. 2008 Nov;31(11):1497-507 - PubMed
  7. Sci Pharm. 2011 Jun;79(2):375-86 - PubMed
  8. Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1688-93 - PubMed
  9. Int J Pharm. 2000 Sep 25;206(1-2):13-21 - PubMed
  10. J Biomed Mater Res A. 2004 Sep 1;70(3):412-9 - PubMed
  11. Saudi Pharm J. 2009 Jul;17(3):217-25 - PubMed
  12. Int J Pharm. 2002 Mar 20;235(1-2):17-33 - PubMed
  13. Int J Pharm. 2002 Jan 14;231(2):131-44 - PubMed
  14. Int J Pharm. 2004 Mar 19;272(1-2):1-10 - PubMed
  15. Int J Pharm. 2003 Jun 4;258(1-2):165-77 - PubMed
  16. J Pharm Sci. 2005 May;94(5):1124-34 - PubMed
  17. J Pharm Pharmacol. 1993 Aug;45(8):682-6 - PubMed
  18. J Pharm Sci. 1995 Aug;84(8):983-6 - PubMed
  19. Pharm Res. 2006 Dec;23(12):2709-28 - PubMed
  20. Int J Pharm. 2005 Jan 20;288(2):235-44 - PubMed
  21. J Pharm Pharmacol. 2007 May;59(5):645-53 - PubMed
  22. Pharm Res. 1997 Dec;14(12):1691-8 - PubMed
  23. Eur J Pharm Biopharm. 2007 Jun;66(3):303-17 - PubMed
  24. J Control Release. 2002 Dec 13;85(1-3):73-81 - PubMed
  25. Pharm Acta Helv. 1978;53(11):327-32 - PubMed

Publication Types